Sisram Medical announces leadership and board changes effective 2026

Yi Liu will be redesignated from executive director and chairman to a non-executive director, stepping down from his chairman, nomination committee chairman, remuneration committee member, and authorized representative roles. Lior Moshe Dayan, currently an executive director and CEO, will become an executive director, chairman, nomination committee chairman, and authorized representative, ceasing his CEO position due to a work assignment within the group. Rongli Feng will join the remuneration committee, and Chi Fung Leo Chan will become a member of the nomination committee.

Eyal Ben David, president of the international division, will assume the chief executive officer role, with an annual base salary of $279,403. Jiahong Li, an executive director and CFO, will also become co-chief executive officer, receiving an annual base salary of RMB1,260,000. Yifang Wu has resigned as a non-executive director, while Caroline Xiaokui Jin has been appointed as a non-executive director.

These changes reflect a strategic realignment within Sisram Medical’s leadership, impacting key executive and board committee roles as the company approaches 2026.